• A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
• A next generation manufacturing facility for biologics in Maryland
• Cell therapy manufacturing capacity on the West and East Coasts
• Specialty manufacturing in Texas

Pascal Soriot, Chief Executive Officer, AstraZeneca said: "Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation."

Delivering growth: Ambition 2030

These US investments are the first of a series of important steps to help deliver AstraZeneca's ambition to achieve $80 billion in Total Revenue by 2030 as set out in May this year (https://www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html). A key element of our strategy is accelerating the Company's development in the United States. The US is AstraZeneca's largest market, generating 44% of its Total Revenue.[1]

AstraZeneca in the US

AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning 12 states.

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on social media @AstraZeneca (https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)

Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).

References

1. As at Q3 2024 noted in AstraZeneca Q3 Financial Results. Available at:  https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html. Accessed November 2024.